Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...
To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T persistence and function. Additionally, there is a growing trend towards ...
T cells are pivotal mediators of the adaptive immune response, with cytotoxic CD8+ T lymphocytes recognising peptides displayed by MHC class I molecules. This antigen presentation process involves the ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE(R) SL Self-Loading MHC Class I Monomers. The novel reagents for antigen-specific CD8+ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback